Financials Boston Scientific Corporation

Equities

BSX

US1011371077

Advanced Medical Equipment & Technology

Market Closed - Nyse 21:00:02 14/06/2024 BST 5-day change 1st Jan Change
76.76 USD -0.26% Intraday chart for Boston Scientific Corporation -0.45% +32.78%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 63,029 51,478 60,534 66,273 84,691 112,851 - -
Enterprise Value (EV) 1 72,820 58,887 67,674 74,280 92,928 119,274 116,474 112,780
P/E ratio 13.6 x -300 x 61.6 x 103 x 54 x 52.2 x 42.4 x 35.3 x
Yield - - - - - - - -
Capitalization / Revenue 5.87 x 5.19 x 5.09 x 5.23 x 5.95 x 7.05 x 6.42 x 5.85 x
EV / Revenue 6.78 x 5.94 x 5.69 x 5.86 x 6.53 x 7.46 x 6.62 x 5.84 x
EV / EBITDA 23.4 x 19.4 x 16.5 x 20.8 x 22.6 x 25.6 x 22.1 x 19 x
EV / FCF 53 x 52 x 51.4 x 79.2 x 51.9 x 53 x 40 x 29.2 x
FCF Yield 1.89% 1.92% 1.94% 1.26% 1.93% 1.89% 2.5% 3.43%
Price to Book 4.54 x 3.32 x 3.64 x 3.77 x 4.39 x 5.27 x 4.67 x 4.03 x
Nbr of stocks (in thousands) 1,393,824 1,431,921 1,424,992 1,432,311 1,464,983 1,470,180 - -
Reference price 2 45.22 35.95 42.48 46.27 57.81 76.76 76.76 76.76
Announcement Date 05/02/20 03/02/21 02/02/22 01/02/23 31/01/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 10,735 9,913 11,888 12,682 14,240 15,996 17,590 19,297
EBITDA 1 3,111 3,040 4,103 3,574 4,106 4,655 5,279 5,936
EBIT 1 2,800 1,917 3,010 3,241 3,738 4,283 4,813 5,408
Operating Margin 26.08% 19.34% 25.32% 25.56% 26.25% 26.78% 27.36% 28.03%
Earnings before Tax (EBT) 1 687 -138 1,076 1,141 1,985 2,628 3,271 3,868
Net income 1 4,700 -173 985 642 1,570 2,201 2,733 3,271
Net margin 43.78% -1.75% 8.29% 5.06% 11.03% 13.76% 15.54% 16.95%
EPS 2 3.330 -0.1200 0.6900 0.4500 1.070 1.471 1.811 2.175
Free Cash Flow 1 1,375 1,132 1,316 938 1,792 2,251 2,915 3,865
FCF margin 12.81% 11.42% 11.07% 7.4% 12.58% 14.07% 16.57% 20.03%
FCF Conversion (EBITDA) 44.2% 37.24% 32.07% 26.25% 43.64% 48.35% 55.23% 65.12%
FCF Conversion (Net income) 29.26% - 133.6% 146.11% 114.14% 102.29% 106.66% 118.17%
Dividend per Share 2 - - - - - - - -
Announcement Date 05/02/20 03/02/21 02/02/22 01/02/23 31/01/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 3,127 3,026 3,244 3,170 3,242 3,389 3,599 3,527 3,725 3,856 4,021 3,958 4,178 4,233 4,425
EBITDA 1 1,109 1,055 898 892 928 947 1,052 1,011 1,095 1,316 1,143 1,134 1,221 1,321 1,324
EBIT 1 819 781 818 810 833 865 964 919 990 1,012 1,071 1,058 1,144 1,133 1,209
Operating Margin 26.19% 25.81% 25.22% 25.55% 25.69% 25.52% 26.79% 26.06% 26.58% 26.24% 26.62% 26.72% 27.39% 26.77% 27.32%
Earnings before Tax (EBT) 1 120 156 345 245 396 444 426 610 505 608 738.8 744 777.2 709 781
Net income 1 80 97 246 174 126 300 261 505 504 495 539.6 516.6 590.7 621.8 676.7
Net margin 2.56% 3.21% 7.58% 5.49% 3.89% 8.85% 7.25% 14.32% 13.53% 12.84% 13.42% 13.05% 14.14% 14.69% 15.29%
EPS 2 0.0600 0.0700 0.1700 0.1200 0.0900 0.2100 0.1800 0.3400 0.3400 0.3300 0.3603 0.3453 0.3988 0.4102 0.4462
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 02/02/22 27/04/22 27/07/22 26/10/22 01/02/23 26/04/23 27/07/23 26/10/23 31/01/24 24/04/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 9,791 7,409 7,140 8,007 8,237 6,423 3,623 -
Net Cash position 1 - - - - - - - 71.2
Leverage (Debt/EBITDA) 3.147 x 2.437 x 1.74 x 2.24 x 2.006 x 1.38 x 0.6864 x -
Free Cash Flow 1 1,375 1,132 1,316 938 1,792 2,251 2,915 3,865
ROE (net income / shareholders' equity) 19.8% 9.44% 14.1% 14.4% 16.3% 16.3% 16.9% 16.6%
ROA (Net income/ Total Assets) 8.67% 4.49% 7.42% 7.6% 8.87% 8.41% 9.35% 8.2%
Assets 1 54,241 -3,851 13,284 8,446 17,696 26,174 29,223 39,888
Book Value Per Share 2 9.950 10.80 11.70 12.30 13.20 14.60 16.40 19.00
Cash Flow per Share 2 1.300 1.060 1.300 1.060 1.710 2.590 2.970 3.440
Capex 1 461 376 554 588 711 692 735 776
Capex / Sales 4.29% 3.79% 4.66% 4.64% 4.99% 4.33% 4.18% 4.02%
Announcement Date 05/02/20 03/02/21 02/02/22 01/02/23 31/01/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
76.76 USD
Average target price
82.26 USD
Spread / Average Target
+7.16%
Consensus
  1. Stock Market
  2. Equities
  3. BSX Stock
  4. Financials Boston Scientific Corporation
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW